In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes

Acta Psychiatrica Scandinavica

Volumn 127, Issue 5, 2013, Pages 344-354

  Maes, M ^a   Kubera, M ^b   Leunis, J C ^c   Berk, M ^d,e,f,g   Geffard, M ^h   Bosmans, E ⁱ  

^a Maes Clinics at Tria   (Thailand)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c Laboratory Ategis   (Belgium)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e DEAKIN UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^h PSL RESEARCH UNIVERSITY   (France)

ⁱ AML Laboratory   (Belgium)

Author keywords

Chronic fatigue; Cytokines; Depression; Inflammation; Leaky gut; LPS; Oxidative stress

Indexed keywords

AZELAIC ACID; EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; LYSOZYME; NEOPTERIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PEROXIDE; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE;

ADULT; ARTICLE; AUTOIMMUNITY; BACTERIAL TRANSLOCATION; CELLULAR IMMUNITY; COMMENSALISM; CONTROLLED STUDY; DEPRESSION; FATTY ACID OXIDATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; AUTOIMMUNITY; BACTERIAL TRANSLOCATION; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INFLAMMATION; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; MURAMIDASE; NEOPTERIN; NERVOUS SYSTEM; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875300745     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01908.x     Document Type: Article

References (86)

1. Maes M. A review on the acute phase response in major depression. Rev Neurosci 1993;4:407-416.
2. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatr 1995;19:11-38.
3. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203-208.
4. Maes M, Bosmans E, Suy E, Vandervorst C, de Jonckheere C, Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990;24:115-120.
5. Maes M, Stevens WJ, Declerck LS et al.Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatr 1993;17:241-255.
6. Maes M, Scharpé S, Meltzer HY et al.Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994;54:143-160.
7. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:664-675.
8. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-186.
9. Dowlati Y, Herrmann N, Swardfager W et al.A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
10. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-αa) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230-239.
11. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010;125:287-294.
12. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003;8:365-370.
13. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004;19:89-95.
14. GaLEcki P, Szemraj J, Bie_Kiewicz M, Zboralski K, Ga_Ecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009;24:277-286.
15. GaLecki P, Szemraj J, Bieńkiewicz M, Florkowski A, GaLecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009;61:436-447.
16. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007;22:67-73.
17. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:676-692.
18. Maes M, Mihaylova I, Leunis JC. Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett 2007;28:861-867.
19. Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011;135:414-418.
20. Vaziri ND. Causal link between oxidative stress, inflammation, and hypertension. Iran J Kidney Dis 2008;2:1-10.
21. Iovine N, Pursnani S, Voldman A, Wasserman G, Blaser MJ, Weinrauch Y. Reactive nitrogen species contribute to innate host defense against Campylobacter jejuni. Infect Immun 2008;76:986-993.
22. Mander P, Brown GC. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation 2005;2:20.
23. Babior BM. NADPH oxidase: an update. Blood 1999;93:1464-1476.
24. Murr C, Fuchs D, Gössler W et al.Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994;338:223-226.
25. Weiss G, Fuchs D, Hausen A et al.Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993;321:89-92.
26. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett 1995;377:461-464.
27. Murayama R, Kobayashi M, Takeshita A, Yasui T, Yamamoto M. MAPKs, activator protein-1 and nuclear factor-κ?B mediate production of interleukin-1β-stimulated cytokines, prostaglandin E2 and MMP-1 in human periodontal ligament cells. J Periodontal Res 2011;46:568-575.
28. Mccubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 2006;8:1775-1789.
29. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29:117-124.
30. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011;32:7-24.
31. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979;23:403-411.
32. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-433.
33. Wischmeyer PE. Glutamine: role in gut protection in critical illness. Curr Opin Clin Nutr Metab Care 2006;9:607-612.
34. Chan ED, Riches DW. IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001;280:C441-C450.
35. Lin WN, Lin CC, Cheng HY, Yang CM. Regulation of cyclooxygenase-2 and cytosolic phospholipase A2 gene expression by lipopolysaccharide through the RNA-binding protein HuR: involvement of NADPH oxidase, reactive oxygen species and mitogen-activated protein kinases. Br J Pharmacol 2011;163:1691-1706.
36. Check J, Byrd CL, Menio J, Rippe RA, Hines IN, Wheeler MD. Src kinase participates in LPS-induced activation of NADPH oxidase. Mol Immunol 2010;47:756-762.
37. Peng T, Lu X, Feng Q. NADH oxidase signaling induces cyclooxygenase-2 expression during lipopolysaccharide stimulation in cardiomyocytes. FASEB J 2005;19:293-295.
38. Pai K, Sodhi A. Effect of cisplatin, rIFN-Y, LPS and MDP on release of H2O2, O2- and lysozyme from human monocytes in vitro. Indian J Exp Biol 1991;29:910-915.
39. Lewis CE, Mccarthy SP, Lorenzen J, Mcgee JO. Differential effects of LPS, IFN-gamma and TNF alpha on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity. Immunology 1990;69:402-408.
40. Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D. The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. JPEN J Parenter Enteral Nutr 2003;27:241-245.
41. Quan ZF, Yang C, Li N, Li JS. Effect of glutamine on change in early postoperative intestinal permeability and its relation to systemic inflammatory response. World J Gastroenterol 2004;10:1992-1994.
42. Schietroma M, Carlei F, Cappelli S, Amicucci G. Intestinal permeability and systemic endotoxemia after laparotomic or laparoscopic cholecystectomy. Ann Surg 2006;243:359-363.
43. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009;43:163-172.
44. Geffard CM, Bodet D, Martinet Y, Dabadie M-P. Detection of the specific IgM and IgA circulating in sera of multiple sclerosis patients: interest and perspectives. Immuno-Analyse Biol Spec 2002;17:302-310.
45. Geffard M, Bodet D, Dabadie MP, Arnould L. Identification of antibodies in sera of breast cancer patients. Immuno-Analyse Biol Spec 2003;18:248-253.
46. March CJ, Mosley B, Larsen A et al.Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985;315:641-647.
47. Varella Morandi Junqueira-Franco M, Ernesto Troncon L, Garcia Chiarello P, Do Rosário Del Lama Unamuno M, Afonso Jordao A, Vannucchi H. Intestinal permeability and oxidative stress in patients with alcoholic pellagra. Clin Nutr 2006;25:977-983.
48. Tyagi E, Agrawal R, Nath C, Shukla R. Effect of melatonin on neuroinflammation and acetylcholinesterase activity induced by LPS in rat brain. Eur J Pharmacol 2010;640:206-210.
49. Mehlhase J, Gieche J, Ullrich O, Sitte N, Grune T. LPS-induced protein oxidation and proteolysis in BV-2 microglial cells. IUBMB Life 2000;50:331-335.
50. Courtois F, Seidman EG, Delvin E et al.Membrane peroxidation by lipopolysaccharide and iron-ascorbate adversely affects Caco-2 cell function: beneficial role of butyric acid. Am J Clin Nutr 2003;77:744-750.
51. Yerer MB, Aydogan S, Yapislar H, Yalcin O, Kuru O, Baskurt OK. Melatonin increases glutathione peroxidase activity and deformability of erythrocytes in septic rats. J Pineal Res 2003;35:138-139.
52. Sah SP, Tirkey N, Kuhad A, Chopra K. Effect of quercetin on lipopolysaccharide induced-sickness behavior and oxidative stress in rats. Indian J Pharmacol 2011;43:192-196.
53. Hall DM, Buettner GR, Oberley LW, Xu L, Matthes RD, Gisolfi CV. Mechanisms of circulatory and intestinal barrier dysfunction during whole body hyperthermia. Am J Physiol Heart Circ Physiol 2001;280:H509-H521.
54. Assimakopoulos SF, Scopa CD, Vagianos CE. Pathophysiology of increased intestinal permeability in obstructive jaundice. World J Gastroenterol 2007;13:6458-6464.
55. Visser J, Rozing J, Sapone A, Lammers K, Fasano A. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci 2009;1165:195-205.
56. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:416-422.
57. Maes M, Coucke F, Leunis JC. Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:739-744.
58. Troppmair J, Nachbaur K, Herold M et al.In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol 1988;74:392-397.
59. Lehner MD, Hartung T. Endotoxin tolerance-mechanisms and beneficial effects in bacterial infection. Rev Physiol Biochem Pharmacol 2002;144:95-141.
60. Draisma A, Pickkers P, Bouw MP, Van Der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009;37:1261-1267.
61. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006;10:233.
62. Balkhy HH, Heinzel FP. Endotoxin fails to induce IFN-gamma in endotoxin-tolerant mice: deficiencies in both IL-12 heterodimer production and IL-12 responsiveness. J Immunol 1999;162:3633-3638.
63. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004;10:71-84.
64. Melo ES, Barbeiro HV, Ariga S et al.Immune cells and oxidative stress in the endotoxin tolerance mouse model. Braz J Med Biol Res 2010;43:57-67.
65. Falchuk KR, Perrotto JL, Isselbacher KJ. Serum lysozyme in Crohn's disease. A useful index of disease activity. Gastroenterology 1975;69:893-896.
66. Mallas E, Terry JM, Asquith P, Cooke WT. Serum lysozyme in inflammatory bowel and coeliac disease. J Clin Pathol 1976;29:598-600.
67. Torsteinsdóttir I, Hâkansson L, Hällgren R, Gudbjörnsson B, Arvidson NG, Venge P. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:1249-1254.
68. Tew JG, Scott RL, Donaldson DM. Plasma beta-lysin and lysozyme following endotoxin administration and the generalized Shwartzman reaction. Proc Soc Exp Biol Med 1971;136:473-478.
69. Takada K, Ohno N, Yadomae T. Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infect Immun 1994;62:1171-1175.
70. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996;711:163-174.
71. Plata-Salaman CR. Interferons and central regulation of feeding. Am J Physiol 1992;263:R1222-1127.
72. Bluthé RM, Walter V, Parnet P et al.Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. CR Acad Sci III 1994;317:499-503.
73. De La Garza R II, Asnis GM, Fabrizio KR, Pedrosa E. Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats. Psychopharmacology 2005;179:356-365.
74. Engeland CG, Kavaliers M, Ossenkopp KP. Sex differences in the effects of muramyl dipeptide and lipopolysaccharide on locomotor activity and the development of behavioral tolerance in rats. Pharmacol Biochem Behav 2003;74:433-447.
75. Swiergiel AH, Dunn AJ. Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests. Pharmacol Biochem Behav 2007;86:651-659.
76. Frenois F, Moreau M, O'connor J et al.Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007;32:516-531.
77. Maes M. "Functional" or "psychosomatic" symptoms, e.g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett 2009;30:564-573.
78. Bailey MT, Engler H, Powell ND, Padgett DA, Sheridan JF. Repeated social defeat increases the bactericidal activity of splenic macrophages through a Toll-like receptor-dependent pathway. Am J Physiol Regul Integr Comp Physiol 2007;293:R1180-R1190.
79. Munhoz CD, Lepsch LB, Kawamoto EM et al.Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-kappaB in the frontal cortex and hippocampus via glucocorticoid secretion. J Neurosci 2006;26:3813-3820.
80. Wiest R. Bacterial translocation. Bioscience Microflora 2005;24:61-90.
81. Todar K. Todar's online textbook of bacteriology. http://www.textbookofbacteriology.net/
82. Pasternak BA, D'mello S, Jurickova II et al.Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis 2010;16:856-869.
83. Maes M, Twisk FN, Kubera M, Ringel K, Leunis JC, Geffard M. Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord 2012;136:909-917.
84. Soczynska JK, Kennedy SH, Woldeyohannes HO et al.Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med 2011;13:93-116.
85. Wonisch W, Falk A, Sundl I, Winklhofer-Roob BM, Lindschinger M. Oxidative stress increases continuously with BMI and age with unfavourable profiles in males. Aging Male 2012;52:230.
86. Smith DF, Gerdes LU. Meta-analysis on anxiety and depression in adult celiac disease. Acta Psychiatr Scand 2012;125:189-193.